(News Bulletin 247) – Celyad announced on Friday the appointment of Georges Rawadi as Chief Executive Officer with the mission of ensuring the next phase of growth for the biotechnology company.
The action of the specialist in therapies based on chimeric antigen receptor T lymphocytes (CAR-T) rose by 3.5% on Euronext Brussels and Paris following this announcement.
Rawadi – who has more than 20 years of experience in the pharmaceutical and biotechnology sector – knows Celyad well, having spent four years there as vice president of business development and intellectual property, between 2014 and 2018. .
The executive, who also served as vice-president of business development at Cellectis, will replace Michel Lussier, a member of the board of directors who previously held the role of CEO on an interim basis.
In his new role, Georges Rawadi will be responsible for ensuring the next phase of growth for the company, which is seeking to make the assets derived from its intellectual property profitable after having abandoned all of its clinical research programs.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
